GlassScriptPhysician profile
Tamara Ann Fuller
NPI 1891420154
$2,444.53
in general payments reported to CMS, 2019-2025
17 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $175 · 2023: $41.48 · 2024: $1,906 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177 · Travel and Lodging: $1,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,177.22 |
| Travel and Lodging | $1,092.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aesculap, INC. | $1,403.16 | 2024 | No Applicable Marketed Product Name |
| Boston Scientific Corporation | $207.46 | 2024-2025 | Intracept Rf Probe, Watchman Flx |
| Insulet Corporation | $142.86 | 2025 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $124.99 | 2022 | |
| Integra Lifesciences Corporation | $98.58 | 2024-2025 | Codman Hakim, Cusa Clarity, Codman Certas |
| Astrazeneca Pharmaceuticals LP | $75.05 | 2024 | Andexxa |
| Ucb, INC. | $67.81 | 2024 | Briviact |
| Medtronic, INC. | $62.76 | 2025 | Mazor X System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.00 | 2022 | |
| Kerecis Limited | $42.52 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Stryker Corporation | $36.26 | 2025 | Augment Injectable |
| Ethicon US, LLC | $35.83 | 2024 | Stratafix, Surgicel Nu-Knit |
| Corium, LLC | $22.28 | 2023 | Azstarys |
| Mimedx Group, INC. | $19.89 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.20 | 2023 | Leqvio |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $18.25 | 2025 | Arikayce |
| Merz Pharmaceuticals, LLC | $17.63 | 2024 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.